Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients

被引:18
作者
Blank, S. [1 ]
Stange, A. [2 ]
Sisic, L. [1 ]
Roth, W. [3 ]
Grenacher, L. [4 ]
Sterzing, F. [5 ]
Burian, M. [1 ]
Jaeger, D. [2 ]
Buechler, M. [1 ]
Ott, K. [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Surg, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
[3] Heidelberg Univ, Inst Pathol, Heidelberg, Germany
[4] Heidelberg Univ, Dept Diagnost & Intervent Radiol, Heidelberg, Germany
[5] Heidelberg Univ, Dept Radiat Oncol & Radiat Therapy, Heidelberg, Germany
关键词
Esophagogastric cancer; Nonresponder; Prognosis; Morbidity; Mortality; HISTOPATHOLOGICAL TUMOR-REGRESSION; SQUAMOUS-CELL CARCINOMA; ESOPHAGEAL CANCER; NEOADJUVANT CHEMOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; GASTRIC-CANCER; RECTAL-CANCER; SURGERY; TRIAL;
D O I
10.1007/s00423-012-1034-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Preoperative treatment is nowadays standard for locally advanced esophagogastric cancer in Europe. Surprisingly, little attention has been paid to nonresponders so far. The aim of our retrospective exploratory study was the comparison of responder, nonresponder, and primary resected patients in respect of outcome considering the tumor entity. From 2001-2011, 607 patients with locally advanced esophagogastric carcinoma (adenocarcinoma of the esophagogastric junction (AEG), n = 293; squamous cell cancer (SCC), n = 111; gastric cancer, n = 203) after preoperative treatment (n = 281) or primary resection (n = 326) were included. Histopathological response evaluation (Becker criteria) was available for 263. A total of 76/263 (28.9 %) were responders (< 10 % residual tumor). There was an association of response with increased R0 resections (p < 0.001) but also with a higher complication rate (p = 0.008) compared to nonresponse and primary surgery. Mortality was not influenced. Increased R0 resections after response were confirmed in every tumor entity (AEG, p = 0.010; SCC, p = 0.023; gastric cancer, p = 0.006). Median survival was best for responders with 43.5 months [95 % confidence interval (CI), 27.9-59.1], followed by nonresponders with 24.3 months (95 % CI, 21.6-27.0) and primary resected patients with 20.8 months (95 % CI, 17.7-23.9; p = 0.002). AEG (p = 0.012) and gastric cancer (p = 0.017) revealed identical results, but in the subgroup of SCC, the survival of nonresponders (median, 11.6 months; 95 % CI, 6.9-16.3) was even worse than for primary resected patients (median, 23.8 months; 95 % CI, 1.7-46.0; p = 0.012). The histopathological response rate was low. Generally, nonresponding patients with AEG or gastric cancer seem not to have a disadvantage compared to primary resected patients, but nonresponders with SCC have a worse prognosis, which strengthens the demand for a critical patient selection in surgery for this tumor entity.
引用
收藏
页码:211 / 220
页数:10
相关论文
共 31 条
  • [1] Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I).: A comparison of two phase II trials with long-term follow-up
    Bader, Franz G.
    Lordick, Florian
    Fink, Ulrich
    Becker, Karen
    Hoefler, Heinz
    Busch, Raymonde
    Siewert, Joerg R.
    Ott, Katja
    [J]. ONKOLOGIE, 2008, 31 (07): : 366 - 372
  • [2] Bartels H, 1998, BRIT J SURG, V85, P840
  • [3] Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas A Summary of 480 Cases
    Becker, Karen
    Langer, Rupert
    Reim, Daniel
    Novotny, Alexander
    zum Buschenfelde, Christian Meyer
    Engel, Jutta
    Friess, Helmut
    Hofler, Heinz
    [J]. ANNALS OF SURGERY, 2011, 253 (05) : 934 - 939
  • [4] Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
  • [5] Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients
    Blank, Susanne
    Blaeker, Hendrik
    Schaible, Anja
    Lordick, Florian
    Grenacher, Lars
    Buechler, Markus
    Ott, Katja
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2012, 397 (01) : 45 - 55
  • [6] Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis
    Bollschweiler, E.
    Metzger, R.
    Drebber, U.
    Baldus, S.
    Vallbohmer, D.
    Kocher, M.
    Holscher, A. H.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (02) : 231 - 238
  • [7] The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas
    Brücher, BLDM
    Becker, K
    Lordick, F
    Fink, U
    Sarbia, M
    Stein, H
    Busch, R
    Zimmermann, F
    Molls, M
    Höfler, H
    Siewert, JR
    [J]. CANCER, 2006, 106 (10) : 2119 - 2127
  • [8] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, David
    Allum, William H.
    Stenning, Sally P.
    Thompson, Jeremy N.
    Van de Velde, Cornelis J. H.
    Nicolson, Marianne
    Scarffe, J. Howard
    Lofts, Fiona J.
    Falk, Stephen J.
    Iveson, Timothy J.
    Smith, David B.
    Langley, Ruth E.
    Verma, Monica
    Weeden, Simon
    Chua, Yu Jo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) : 11 - 20
  • [9] Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response
    Geh, J. Ian
    Bond, Simon J.
    Bentzen, Soren M.
    Glynne-Jones, Robert
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 78 (03) : 236 - 244
  • [10] Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy
    Heidecke, CD
    Weighardt, H
    Feith, M
    Fink, U
    Zimmermann, F
    Stein, HJ
    Siewert, JR
    Holzmann, B
    [J]. SURGERY, 2002, 132 (03) : 495 - 501